Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Michael Panny, MD, Katharina Troppan, MD, Peter Neumeister, MD, Thomas Nösslinger, MD, Felix Keil, MD

Blood (2016) 128 (22): 5413.

https://doi.org/10.1182/blood.V128.22.5413.5413

Published: 2016

Journal Articles

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Marco Bischof, Christine Beham-Schmid, MD, Hildegard T. Greinix, MD, Peter Neumeister, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 2444.

https://doi.org/10.1182/blood.V126.23.2444.2444

Published: 2015

Journal Articles

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

Katharina Troppan, MD, Kerstin Wenzl, MSc, Peter Neumeister, MD, Christine Beham-Schmid, MD, Martina Przekopowitz, Hildegard T. Greinix, MD, Helmut Schaider, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 3890.

https://doi.org/10.1182/blood.V126.23.3890.3890

Published: 2015

Journal Articles

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

Alexander JA Deutsch, PhD, Beate Rinner, PhD, Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Hildegard T. Greinix, MD, Christine Beham-Schmid, MD, Peter Neumeister, MD

Blood (2015) 126 (23): 2674.

https://doi.org/10.1182/blood.V126.23.2674.2674

Published: 2015

Journal Articles

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Alexander J. A. Deutsch, Beate Rinner, Kerstin Wenzl, Martin Pichler, Katharina Troppan, Elisabeth Steinbauer, Daniela Schwarzenbacher, Sonja Reitter, Julia Feichtinger, Sascha Tierling, Andreas Prokesch, Marcel Scheideler, Anne Krogsdam, Gerhard G. Thallinger, Helmut Schaider, Christine Beham-Schmid, Peter Neumeister

Blood (2014) 123 (15): 2367–2377.

https://doi.org/10.1182/blood-2013-08-518878

Published: 2014

Includes: Supplemental data

Journal Articles

Distinct Chemokine Receptor Profile In Chronic Lymphocytic Leukaemia and Richter Transformed Diffuse Large B Cell Lymphomas Compared To Germinal Center B Cells and De Novo Diffuse Large B Cell Lymphomas

Kerstin Wenzl, MSc, Katharina Troppan, MD, Alexander JA Deutsch, Werner Linkesch, MD, Peter Neumeister, MD, Christine Beham-Schmid, MD

Blood (2013) 122 (21): 4852.

https://doi.org/10.1182/blood.V122.21.4852.4852

Published: 2013

Journal Articles

90 Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

Katharina Troppan, MD, Angelika Valentin, MD, Werner Linkesch, MD

Blood (2013) 122 (21): 5123.

https://doi.org/10.1182/blood.V122.21.5123.5123

Published: 2013

NARROW

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Distinct Chemokine Receptor Profile In Chronic Lymphocytic Leukaemia and Richter Transformed Diffuse Large B Cell Lymphomas Compared To Germinal Center B Cells and De Novo Diffuse Large B Cell Lymphomas

90 Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

Email alerts

ASH Publications

American Society of Hematology

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Distinct Chemokine Receptor Profile In Chronic Lymphocytic Leukaemia and Richter Transformed Diffuse Large B Cell Lymphomas Compared To Germinal Center B Cells and De Novo Diffuse Large B Cell Lymphomas

90 Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only